Photo illustration: Jaap Arriens/NurPhoto via Getty Images

Facebook stock was down double digits after hours Wednesday after the company reported that it missed revenue and user growth estimates for the second quarter and predicted it will continue to see slowed revenue growth in future quarters.

Why it matters: For months the tech giant seemed unstoppable, posting record earnings continually despite months of public relations fallout and product changes. Today's earnings show that product changes to address user privacy and engagement are starting to affect the company's bottom line.

"We expect our revenue growth rates to decline by high single digit percentages from prior quarters sequentially in both Q3 and Q4"
Facebook CFO David Wehner

Facebook CEO Mark Zuckerberg said that big investments in security will begin to affect the company's profitability. COO Sheryl Sandberg said that GDPR, the sweeping European privacy law that went into effect in May, didn't have a big impact on revenue.

By the numbers (missed):

  • Revenue: $13.23 billion vs. $13.3 billion expected
  • Monthly Active Users (MAUs): 2.23 billion vs. 2.25 billion expected
  • Daily Active Users (DAUs): 1.47 billion vs. 1.49 billion expected

By the numbers (hit/up):

  • EPS: $1.74 vs. $1.71 expected
  • Advertising: $13.04 billion, up 42% from $9,164 billion last year.
  • Mobile Advertising: ~91% of advertising revenue for the second quarter of 2018, up from ~87% of advertising revenue in the second quarter of 2017.

The news was surprising, given that the company's stock hit an all-time high just minutes before reporting earnings. Analysts were bullish earlier this week for two reasons:

  1. Google hit earnings Monday, despite some of the same problems also plaguing Facebook, like Europe's sweeping data privacy law that went into effect in late May and user privacy backlash this quarter around data-based advertising.
  2. The company has continued to meet investor expectations for the past year, despite many controversies, like a Russian meddling hearing on Capitol Hill.

Go deeper

Updated 42 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Politics: Chris Christie: Wear a mask "or you may regret it — as I did" — Senate Democrats block vote on McConnell's targeted relief bill.
  2. Business: New state unemployment filings fall.
  3. Economy: Why the stimulus delay isn't a crisis (yet).
  4. Health: FDA approves Gilead's remdesivir as a coronavirus treatment How the pandemic might endMany U.S. deaths were avoidable.
  5. Education: Boston and Chicago send students back home for online learning.
  6. World: Spain and France exceed 1 million cases.

FBI: Russian hacking group stole data after targeting local governments

FBI Headquarters. Photo: Mark Wilson/Getty Images

Energetic Bear, a Russian state-sponsored hacking group, has stolen data from two servers after targeting state and federal government networks in the U.S. since at least September, the FBI and Cybersecurity and Infrastructure Security Agency said on Thursday.

Driving the news: Director of National Intelligence John Ratcliffe announced Wednesday that Iran and Russia had obtained voter registration information that could be used to undermine confidence in the U.S. election system.

FDA approves Gilead's remdesivir as a coronavirus treatment

A production line of Remdesivir. Photo: Fadel Dawood/picture alliance via Getty Images

Gilead Sciences on Thursday received approval from the Food and Drug Administration for remdesivir, an antiviral treatment that has shown modest results against treating COVID-19.

Why it matters: It's the first and only fully FDA-approved drug in the U.S. for treating the coronavirus.